NASDAQ:INAB - Nasdaq - US45674E1091 - Common Stock - Currency: USD
Overall INAB gets a fundamental rating of 1 out of 10. We evaluated INAB against 561 industry peers in the Biotechnology industry. INAB has a bad profitability rating. Also its financial health evaluation is rather negative. INAB is valued expensive and it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -145.33% | ||
ROE | -210.23% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.02 | ||
Debt/FCF | N/A | ||
Altman-Z | -11.39 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 4.08 | ||
Quick Ratio | 4.08 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:INAB (5/21/2025, 3:37:34 PM)
0.127
0 (-2.31%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.71 | ||
P/tB | 0.71 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -145.33% | ||
ROE | -210.23% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.02 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 10.19% | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 4.08 | ||
Quick Ratio | 4.08 | ||
Altman-Z | -11.39 |